Press release
Brain Metastases Pipeline Developments Report 2025: Cutting-Edge Therapeutics and Clinical Momentum Across Major Indications
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Brain Metastases Pipeline Outlook Report [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Brain Metastases Pipeline Report
* On 21 November 2025, Memorial Sloan Kettering Cancer Center conducted a study is to see if Cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). The researchers would like to see whether Cs-131 prevents brain tumors from growing back after surgery.The researchers will compare Cs-131 brachytherapy (which occurs during brain surgery) with the usual approach of brain surgery without brachytherapy. The researchers will compare both the effectiveness and safety of the two approaches.
* DelveInsight's Brain Metastases pipeline report depicts a robust space with 40+ active players working to develop 45+ pipeline therapies for Brain Metastases treatment.
* The leading Brain Metastases Companies such as HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.
* Promising Brain Metastases Pipeline Therapies such as GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib and others.
Learn how leading Brain Metastases Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Brain Metastases Clinical Trials Assessment [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Brain Metastases Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Brain Metastases Pipeline Report also highlights the unmet needs with respect to the development of Brain Metastases.
Brain Metastases Overview
Brain metastases are a common complication of cancer and the most common type of brain tumor. Anywhere from 10% to 26% of patients who die from their cancer will develop brain metastases. While few cancers that metastasize to the brain can be cured using conventional therapies, long-term survival and palliation are possible with minimal adverse effects to patients. Increasingly, neuro-cognition and quality of life are being recognized as important endpoints for patients as survival continues to increase.
Brain Metastases Emerging Drugs Profile
* ANG1005: Angiochem
ANG1005 is a novel targeted taxane derivative that is the first oncology product to leverage Angiochem's technology platform to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 is an Angiopep-2 paclitaxel conjugate that gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain.
* Azeliragon: Cantex Pharmaceuticals, Inc.
Azeliragon, is an oral, small molecule, administered once-daily, that inhibits RAGE interactions with its natural ligands, including HMGB1 and S100 proteins, in the tumor microenvironment. Activation of RAGE by these ligands stimulates cancer and its progression and metastasis and resistance to cancer treatment.
* AZD3759: Alpha Biopharma Ltd.
Zorifertinib (AZD3759) is a type of reversible new generation EGFR TKI, which has a strong ability to penetrate the bloodstream, cerebrospinal fluid, and can reach blood volume in the tissue. It is currently investigated for brain metastases and completed Phase II/III trial in July 2022.
From early-stage research to late-phase Brain Metastases Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Brain Metastases Treatment Drugs [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Brain Metastases Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Brain Metastases with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Brain Metastases Treatment.
* Brain Metastases Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Brain Metastases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Brain Metastases market.
Brain Metastases Companies
HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.
Brain metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Brain Metastases Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Stay updated with the latest Brain Metastases Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Brain Metastases Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Brain Metastases Pipeline Report
* Coverage- Global
* Brain Metastases Companies- HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.
* Brain Metastases Pipeline Therapies- GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib and others.
* Brain Metastases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Brain Metastases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest Brain Metastases Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Brain Metastases Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Brain metastases: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Brain metastases- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* ANG1005: Angiochem
* Mid Stage Products (Phase II)
* Paxalisib: Kazia Therapeutics
* Early Stage Products (Phase I)
* MW151: ImmunoChem Therapeutics, LLC
* Preclinical and Discovery Stage Products
* JBI-2174: Jubilant Therapeutics
* Inactive Products
* Brain metastases Key Companies
* Brain metastases Key Products
* Brain metastases- Unmet Needs
* Brain metastases- Market Drivers and Barriers
* Brain metastases- Future Perspectives and Conclusion
* Brain metastases Analyst Views
* Brain metastases Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=brain-metastases-pipeline-developments-report-2025-cuttingedge-therapeutics-and-clinical-momentum-across-major-indications]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/brain-metastases-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Brain Metastases Pipeline Developments Report 2025: Cutting-Edge Therapeutics and Clinical Momentum Across Major Indications here
News-ID: 4285968 • Views: …
More Releases from ABNewswire
Non Muscle Invasive Bladder Cancer Pipeline Insights Report 2025: Emerging Thera …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further…
Dr. Cheng LONG: Innovator and Academic Contributor in the Field of Data Science
In the fast-paced realm of data science and machine learning, professionals with a solid academic background and extensive practical experience are becoming the key drivers of industry progress. Dr. Cheng LONG, currently serving as a Associate Data Scientist at Microsoft, is an outstanding representative of this field. He graduated from Florida State University with a Ph.D. in Statistics, which laid a solid theoretical foundation for his work in data modeling…
ENDRA Life Sciences (NASDAQ: NDRA) Advances "Yield-to-Innovation" Strategy to Ac …
ENDRA Life Sciences (NASDAQ: NDRA) is drawing renewed attention from investors with the rollout of its "Yield-to-Innovation" strategy, a financial and operational framework designed to strengthen long-term growth while advancing the Company's breakthrough TAEUS Registered liver imaging technology.
The model centers on an institutionally managed treasury program engineered to generate stable, non-dilutive returns. Rather than relying solely on traditional equity financing-often expensive and dilutive for early-stage companies-ENDRA's treasury structure provides a…
Datavault AI (NASDAQ: DVLT) Bullish Signals Trigger Strong Upside - Similar Patt …
Datavault AI Inc. (NASDAQ: DVLT) erupted +46.55% on Friday as trading volume surged to 1.5 times above average, marking one of the stock's strongest technical sessions of the quarter. After persistent pressure widely attributed to naked short activity, Friday's powerful reversal suggests that efforts to suppress DVLT's price may now be unwinding in dramatic fashion.
A cluster of high-reliability bullish technical indicators fired simultaneously, including:
- Break above the 20-Day Moving Average-…
More Releases for Brain
Brain Training Apps Market Boosting the Brain: The Rise of Brain Training Apps a …
Brain Training Apps Market Assessment worth $ 44.43 Billion by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Brain Training Apps Market- by App Type (Memory, Attention, Language, Executive Function, Visual/spatial, and Other App Types), User Type (Android, iOS and Other User Types), Trends, Industry Competition Analysis, Revenue and Forecast To 2024-2031."
Get a free sample copy of…
Nutrient Survival Champions Brain Health During Alzheimer's & Brain Awareness Mo …
This June, Nutrient Survival is reminding people that nourishing your mind is as crucial as feeding your body, offering a revolutionary BrainCare® line.
Reno, NV (June 5, 2024) - As June marks Alzheimer's & Brain Awareness Month, Nutrient Survival, veteran-led pioneer in nutritional innovation, stands at the forefront of promoting
cognitive well-being with its revolutionary BrainCare® line and Brain Omega 3 Bar®. With alarming statistics highlighting the prevalence of brain-related ailments among…
Brain Monitoring Device Market - Harnessing the Power of Neurotechnology: Brain …
Newark, New Castle, USA: The "Brain Monitoring Device Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Brain Monitoring Device Market: https://www.growthplusreports.com/report/brain-monitoring-device-market/7889
This latest report researches the industry structure,…
Supercharge Your Brain: Revolutionary Brain Health Supplements for Improved Brai …
The global 𝐁𝐫𝐚𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡 𝐒𝐮𝐩𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐬 market is estimated to attain a significant valuation by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand during the forecast period, 2021-2031.
The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of the Brain Health Supplements industry. The current…
Global Wearable Brain Devices Market Growth by 2030 - Advanced Brain Monitoring …
The research report based on the Global Wearable Brain Devices Industry offers the detailed study of each and every aspect coupled with the Wearable Brain Devices market. The report also analyzes all the strategic developments made in the Wearable Brain Devices sector. The research report offers detailed and accurate numerical data on costs, revenues, sales, profits, etc. The market report narrowly analyzes all the key growth factors that are considered…
Retro X Focus Nootropic Brain Booster - SUPERCHARGED BRAIN PERFORMANCE!
Retro X Focus Nootropic Brain Booster is a state-of-the-art nootropic that employs vitamins, vital nutrients, plus amino acids to assist you to think quicker, cleverer, smarten your memory, and improve attention and leave you feeling invigorated. The water-soluble extracts, which are useful in product additives, function to rejuvenate studying approaches and thinking.
Official Online Store - https://www.allnutritionhub.com/get-retro-x-focus-nootropic
How does the Retro X Focus Function?
It is common knowledge that we must work out…
